Leadership of the UK Chinese Business Association (UKCBA), including chairman, Mr. Jinlong Zhang, and secretary-general and executive vice chairman, Mr. Jie Yin, along with the UK delegation, visited HighTide Therapeutics, Inc.
July 17, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, June 24, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that data from the Phase 2a clinical trial of HTD1801, a first-in-class gut-liver anti-inflammatory metabolic modulator for patients with nonalcoholic
June 24, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, May 15, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the discovery and development of first-in-class multifunctional therapies for metabolic and digestive
May 15, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, March 16, 2023— HighTide Therapeutics Inc. (“HighTide”), today announced that Dr. Liping Liu, founder and CEO of HighTide, was selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023.
March 16, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, February 6, 2023 — HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive
February 06, 2023
Learn More
ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases,
February 01, 2023
Learn More
© 2023 HighTide Therapeutics, Inc.